Stay updated with breaking news from Immune Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) – Equities research analysts at Wedbush issued their Q1 2024 EPS estimates for Alpine Immune Sciences in a research note issued to investors on Friday, March 24th. Wedbush analyst R. Driscoll anticipates that the biotechnology company will post earnings per share of ($0.23) for the quarter. Wedbush […]
Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) – Oppenheimer issued their Q1 2024 earnings per share estimates for shares of Alpine Immune Sciences in a research note issued to investors on Friday, March 24th. Oppenheimer analyst M. Breidenbach expects that the biotechnology company will post earnings of ($0.41) per share for the quarter. The […]
Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) had its price objective increased by HC Wainwright from $8.00 to $11.00 in a research report report published on Friday morning, The Fly reports. HC Wainwright also issued estimates for Alpine Immune Sciences’ Q2 2023 earnings at ($0.35) EPS and Q3 2023 earnings at ($0.39) EPS. Separately, Morgan […]
23.03.2023 - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for ...
Stock Analysts’ price target changes for Friday, March 24th: AirBoss of America (OTCMKTS:ABSSF) had its price target lowered by TD Securities from C$14.00 to C$11.50. Accolade (NASDAQ:ACCD) had its target price raised by Truist Financial Co. to $17.00. Accenture (NYSE:ACN) had its price target boosted by Citigroup Inc. from $300.00 to $310.00. Citigroup Inc. currently […]